OpenBCI

Phase A — Understand the business

Lens 1 · Company Overview

OpenBCI builds affordable, open-source biosensing hardware — boards and headsets that let anyone "sample the electrical activity of their body" (EEG brain, EMG muscle, EKG/PPG heart, EDA skin) — and gives the software and design files away free under open licences. The wedge is explicit and unchanged for 13 years: lower the barrier to entry for human-computer-interface technology. The company says it has shipped more than 40,000 tools for neuroscience to more than 100 countries.

Founded late 2013 in Brooklyn off a successful Kickstarter, by Joel Murphy and Conor Russomanno (now CEO & co-founder). Headcount is small — third-party trackers put it in the ~20–50 range (n/a — exact count not disclosed).

Product ladder (the two businesses inside one company):

1. Open-hardware research/maker tier — the actual revenue engine today.

• Cyton — 8-channel bio-sensing board (ADS1299 TI front-end + PIC MCU), the published-research workhorse; ~$999. Cyton + Daisy expansion → 16 channels.
• Ganglion — 4-channel low-cost board; launched 2015 via Kickstarter at $99, now listed ~$499. (The 5× price walk-up off the Kickstarter floor is itself a tell about volume economics — see Lens 5.)
• Ultracortex "Mark IV" — open, 3D-printed EEG headset; design files free on GitHub, printed/sold via Voodoo Manufacturing.
• GUI + open SDKs + a large GitHub org — the free layer that drives the hardware pull-through and the academic citation moat (Lens 3).

1. Galea — the one venture-scale swing. A premium multi-modal biosensing headset that bolts EEG + EMG + EDA + PPG + eye-tracking onto an XR head-mounted display. Unveiled late 2020 with Valve + Tobii; the VR partner later became Varjo (Galea integrated into the Varjo Aero), and the latest SKU is Galea + Pupil Labs "Neon" — billed as the first untethered all-in-one brain/body/eye headset, shipping now. Beta pre-orders opened Aug-2024 at ~$25,000/unit (Varjo Aero + Galea kit listed ~$22,500). Marketed under a distinct brand at galea.co, but on the public record it remains an OpenBCI product line, not a separately-financed entity — there is no evidence of an independent Galea funding round.

Customers (research-layer: customers.csv is empty → all ``): universities, neuroscience labs, educators, hobbyists/makers for the open tier; for Galea, "innovation teams across gaming, entertainment, aviation, simulation & training, automotive human-factors". No named marquee logo and no concentration data is disclosed.

Contract structure: transactional hardware sale, not recurring. There is no disclosed SaaS/data ARR line — the revenue is a unit-shipped, gross-margin-on-a-board model with a long-lead enterprise headset on top. This is the single most important structural fact and recurs through Lenses 5, 11, 12, 13.

Lens 2 · Supply Chain

Upstream inputs → OpenBCI → end user, named where the record allows:

• Analog front-end silicon: Texas Instruments ADS1299 (the 8-channel, 24-bit biopotential ADC) is the heart of the Cyton/research line — an off-the-shelf, single-vendor part that OpenBCI does not control. Chokepoint: the whole research tier rides one TI converter family; OpenBCI has no custom ASIC and no foundry relationship (contrast Neuralink's custom N1 / Paradromics' custom chip ).
• MCU / connectivity: PIC microcontroller + Bluetooth/RF modules — commodity, multi-source.
• Headset fabrication: the Ultracortex Mark IV is 3D-printed by Voodoo Manufacturing (a contract additive-manufacturing shop) — i.e. outsourced, on-demand manufacturing, low fixed cost but also low scale leverage.
• Galea integration partners — the dependency that matters: the headset is only a headset because of third-party XR + eye-tracking hardware it does not own: Valve → Varjo (the HMD/optics) and Tobii → Pupil Labs Neon (eye-tracking). Single-partner dependency: Galea's roadmap has now pivoted its anchor partner twice (Valve→Varjo, Tobii→Pupil Labs). That instability upstream is a structural risk, not a footnote.
• Distribution: direct e-commerce (shop.openbci.com), global ship to 100+ countries. No distributor or channel concentration disclosed.

Verdict on the chain: asset-light and resilient on the research tier (commodity parts, outsourced print) but fragile on the Galea tier, where the product literally depends on whichever XR/eye-tracking partner is willing to be integrated this year. Names or it didn't happen — and the names here keep changing.

Lens 3 · Competitive Advantages (moats)

OpenBCI's moat is not technological exclusivity (it open-sources its own designs). It is community, brand, and the academic citation network — a genuinely durable but low-monetisation moat:

• Installed base + standardisation. 40,000+ units in 100+ countries means OpenBCI is a de facto teaching and prototyping standard. In the peer scoping literature OpenBCI is one of the most-used consumer/research EEG platforms (behind Emotiv and NeuroSky in raw study count, but the leader on channel flexibility / raw-signal control). Every grad student who learns on a Cyton is a switching-cost seed.
• Open-source flywheel as brand moat. Free GUI/SDK/design-files → community contributions → citations → more hardware pull-through. This is the same moat Emotiv and g.tec lack in pure form, and it is why OpenBCI punches above its ~$4M-revenue weight in mindshare.
• Bargaining power — weak both ways. Over suppliers: none (it is a small buyer of a TI commodity part). Over customers: limited — buyers can drop to a $250 Muse/NeuroSky for casual use, or up to g.tec/clinical rigs for serious work; OpenBCI owns the middle (flexible, hackable, mid-priced) but the middle is contestable. The open licence means a competitor can fork the designs — the brand/community is the only thing that doesn't fork.
• What durable advantage actually exists: mind-share + the citation/education install base. That protects the research-tier revenue from erosion but does not create pricing power and does not scale into the Galea opportunity, where the moat is held by whoever owns the XR platform.

Bottom line: a real but narrow moat that defends a small base — exactly the pattern across the consumer-BCI cohort (cf. emotiv "pioneer that capital forgot", gtec, cognixion "research-tools niche").

Lens 4 · Segments

research-layer: segments.csv is empty — OpenBCI discloses no segment financials. Reconstructed qualitatively from product structure, all /:

By geography: global (100+ countries) but n/a — split not disclosed; the academic/maker base skews US + Europe + a long international tail. The segment story is the whole thesis: a cash-flow-steady but un-scalable open-hardware core, plus a single high-ticket bet (Galea) that is pre-traction. No segment number here is audited.

---

Phase B — Measure performance

(Phase B runs in +private form: SEC-grounded earnings/comps/projection lenses are swapped for funding-trajectory, cap-table, and traction lenses.)

Lens 5 · Funding & Valuation Trajectory (swaps "Earnings Result")

OpenBCI is a capital-light, capital-starved company — the defining quantitative fact, and one where the public sources openly conflict (surfaced, not reconciled):

• Total raised: conflicting marks — PitchBook $3.83M, Tracxn $3.56M over 6 rounds, CB Insights/Crunchbase ~$2.06M over 4 rounds. Use the ~$2–4M lifetime band; do not pretend to a single figure.
• Origin = Kickstarter, not VC. The 2013 founding and the 2015 Ganglion launch were crowdfunded — OpenBCI "raised its 1st [institutional] funding round 8 years after it was founded" (i.e. ~2021). For its first ~8 years it was effectively customer-funded.
• Largest round: a Seed of $1.75M on 29-Sep-2021.
• Latest: a Convertible Note (IV) of $0.2M on 28-Aug-2024 — a small bridge note, not a priced up-round. No priced equity round is on record since the 2021 seed — the same "no priced round in years" signal that flags kernel and emotiv as capital-stranded.
• Investors: BITKRAFT Ventures (gaming/XR-focused — fits the Galea thesis), NaHCO3, re.Mind Capital, Inertia Ventures, plus Kickstarter backers. No crossover fund (no Fidelity/T. Rowe/Coatue) — by the +private overlay's own rule, the absence of a crossover investor is an IPO-distance tell.
• Valuation: n/a — no priced round disclosed; PitchBook lists a profile but no defensible post-money is public.
• Revenue: a third-party scrape gives "~$4M annual revenue, 2026" — low confidence, unaudited, single-source. Treat as order-of-magnitude only.
• Burn signal: raising a $0.2M note in Aug-2024 rather than a Series A says the company is running close to operating break-even on hardware margin (a genuinely impressive sign of discipline) or is unable to clear a priced round at a step-up it will accept — likely both. Either way it is not deploying venture capital at scale, which is the only way the Galea bet gets funded to maturity.

Read: this is a profitable-ish small-hardware business that chose not to (or could not) become a venture rocket. Admirable as a company; structurally not a near-term tradeable.

Lens 6 · Founder & Public-Voice Sentiment (swaps "Earnings Calls")

No earnings calls exist; the analogue is the founder's public narrative (TED, podcasts, Slush), and its arc has shifted in a telling way:

• 2013–2019 tone: democratise neuroscience — open hardware, citizen science, "give everyone the tools." Pure mission.
• 2020–2023 tone: multimodal + the body, not just the brain — Galea reframes OpenBCI from an EEG-board maker to a "merge biometrics with mixed reality" company.
• 2023→ tone (Slush 2023 / TED 2023): the "wearable, neuro-powered personal computer" — Russomanno: "the combination of neurotechnology and mixed reality [is] the future of personal computers" and the long-term goal "Galea Unlimited," one integrated optics+CPU+sensor device.

Sentiment trend: escalating ambition, widening TAM claims, lengthening time-horizon — classic of a founder pulling the story up-market to justify a venture-scale future while the shipping product stays a research board. The thing they stopped emphasising is the humble "$99 board for students"; the thing they added is "the next personal computer." That gap between narrative altitude and revenue reality is the central tension a skeptic prices (Lens 13). Russomanno himself is a credible, mission-driven operator (below) — this is ambition, not promotion — but the rhetoric has run well ahead of the P&L.

Lens 7 · Cap Table & Secondary Marks / Mechanism Comps (swaps "Comps")

Syndicate quality (the +private cap-table read):

• Tier: seed/early specialists, not growth-stage validators. BITKRAFT (a respected gaming/XR fund — thematically perfect for Galea but small-cheque), plus NaHCO3 / re.Mind / Inertia.
• Crossover funds: none → IPO-proximity reads low.
• Secondary marks / mutual-fund markups: n/a — none disclosed; OpenBCI is too small and too rarely-priced for tracked secondary marks.

Peer table — the consumer/research-grade BCI cohort (NOT the implant majors; multiples are meaningless for unprofitable privates, so this maps capital, stage, and verdict, which is the decision-relevant axis). All /:

P/E, EV/Sales, dividend yield, 5-yr ROE: n/a (private, no audited financials). The decision-relevant comp is capital raised vs. mission: OpenBCI has raised the least of the entire cohort while shipping the most units — capital-efficient, but it means it cannot out-spend anyone into the consumer-headset future it describes.

Lens 8 · Funding & Product Catalysts (swaps "Stock-Price Catalysts")

No stock, so the analogue is the events that materially re-rate the private narrative:

• 2013 — Kickstarter founding (the origin event).
• 2015 — Ganglion Kickstarter ($99 board) — set the "accessible" brand.
• late 2020 — Galea unveiled with Valve + Tobii: the single biggest narrative re-rate (research-tool → XR-platform ambition).
• Dec-2021 / 2022 — CES Innovation Awards; AWE Auggie + Unity Aerospace awards for Galea.
• 29-Sep-2021 — the $1.75M seed (only priced round).
• Apr/2023 — Russomanno TED Talk + Slush 2023 "neuro-powered personal computer" vision — peak narrative altitude.
• 2024 — Varjo replaces Valve as XR partner; Galea Beta pre-orders open (Aug-2024, ~$25k); $0.2M convertible note (Aug-2024).
• 2024–25 — Galea + Pupil Labs Neon (untethered) ships.
• 2025 — sponsored MIT Reality Hack 2025; routine team adds.

Pattern: OpenBCI's narrative re-rates on partnership + product-vision events, not financings. The market (such as it is) reacts to who it partners with in XR — which is exactly the dependency Lens 2 flagged as fragile. The thing that would actually re-rate it — a priced Series A led by a growth/crossover fund, or a named enterprise Galea deployment at volume — has not happened.

---

Phase C — Judge people & books

Lens 9 · Management

• Conor Russomanno — Co-founder & CEO. The defining asset and the defining limit. Came to BCI after concussions in college football/rugby; built DIY brain-sensing headsets during an MFA in Design & Technology at Parsons; adjunct at Parsons & NYU Tisch, Research Affiliate at MIT Media Lab; Forbes 30 Under 30 (Science, 2018). Track record — quantified: took an open-source side-project to 40,000+ tools across 100+ countries and two CES Innovation Awards + AWE/Unity awards for Galea. A genuine domain founder + community-builder, not a hired operator.
• Joel Murphy — Co-founder. Hardware/engineering co-founder from the 2013 origin; lower public profile in recent years (n/a — current role/ownership not disclosed).
• Tenure & skin in the game: founder-led for 13 years; given total raise of only ~$2–4M, founder/employee + crowdfunding ownership is presumably very high and dilution low. High alignment.
• Capital-allocation history: disciplined to a fault — built a 40k-unit global install base on a few million dollars, never over-raised, never chased a vanity valuation. The flip side: it has not deployed the capital that a hardware-platform land-grab requires, and the one big swing (Galea) is being funded on fumes (a $0.2M note).
• Founder vs. professional manager: pure founder-mission archetype — optimises for impact and openness over enterprise value capture. That is precisely why it is a category-shaper and a difficult investment: the incentive structure points at "lower the barrier to entry," not "maximise equity return."
• Red flags: none material on the public record — no promotional stock behaviour (it's private), no related-party scandal, no disclosed governance issue. The honest concern is strategic, not ethical: ambition (the "neuro-personal-computer") outrunning balance sheet.

Lens 10 · Forensic Red Flags

No audited financials exist — OpenBCI files nothing with the SEC (no CIK). Standard income-statement / balance-sheet / cash-flow forensics are n/a — private, not disclosed. What a forensic analyst can flag, web-only and unaudited:

• Revenue quality — unknowable but structurally clean. A transactional hardware model has little room for the rev-rec games that flag software names; the risk is the opposite — lumpy, low-margin-on-low-volume, and a "$4M revenue" figure that is a third-party estimate, not a company disclosure.
• The 5× Ganglion price walk ($99→$249→$499) is not an accounting flag but an economics flag: it implies the original Kickstarter price was below sustainable unit cost and volume never delivered the scale to hold it down.
• No going-concern visibility: a $0.2M bridge note as the latest financing means cash runway is genuinely opaque — the most important "red flag" here is simply insufficient disclosure to underwrite it.

Regulatory findings (required sub-section). Per companies/openbci/regulatory/regulatory-findings.md, total_sec_findings: 0 — OpenBCI has no CIK and no EDGAR/SEC enforcement record possible (it is private). The non-SEC web sweep is where the category risk lives:

• No company-specific lawsuit, FTC, FDA, or DOJ action against OpenBCI was found.
• But OpenBCI is named squarely in the neural-data-privacy wave that is the defining regulatory story for the whole consumer-BCI cohort: a Neurorights Foundation report found 29 of 30 neurotech companies provide "no meaningful limitations" on access to brain data, and in April 2025 Democratic members of the US Senate Commerce Committee asked the FTC to investigate consumer brain-data exploitation. Four states now have neural-data laws — Colorado, California, Montana, Connecticut. As a maker of devices that capture raw neural/biometric data, OpenBCI is in scope of this tightening regime even though it has not been individually sanctioned. Its open-source/researcher ethos is a mitigant (it's a tool-maker, not a data-harvesting consumer app), but it is exposure to track.
• Item 3 Legal Proceedings: n/a — no 10-K exists.
• Net: "No material company-specific regulatory or legal findings — verified via SEC EDGAR EFTS (0 LR/AAER, no CIK), targeted web search, as of 2026-06-30. Sector-level neural-data-privacy regulation (FTC referral + four state laws) is a live, named exposure for the category."

---

Phase D — Project & stress-test

Lens 11 · IPO-Readiness & Path-to-Tradeable (swaps "Forward Projection")

No EPS projection is meaningful (private, hardware, no audited revenue) — the +private overlay's lens is path-to-tradeable, and the answer is blunt:

• IPO readiness: ~1 / 5 — among the lowest in the BCI census. It has no priced round since 2021, no crossover investor, ~$2–4M lifetime raise, ~$4M (unaudited, est.) revenue, and no disclosed growth inflection. By every +private tell, a standalone IPO is not on the table this cycle.
• The realistic path-to-tradeable is acquisition, not listing — the identical conclusion the house reached for cognixion ("acquisition-by-a-giant, not an IPO") and the live risk for kernel ("acquisition far likelier than IPO"). Logical acquirers: an XR platform that wants native biosensing (the Galea thesis made real — Valve/Varjo/Meta/Apple-adjacent), a research-instrumentation roll-up, or a larger neurotech consolidating the open-source community + brand.
• Milestones that would unlock an S-1 (none yet visible): (1) a priced Series A led by a growth/crossover fund at a real step-up; (2) a named, repeatable enterprise Galea deployment with disclosed unit volume; (3) double-digit-million, audited, growing revenue with a recurring/data line on top of hardware. Estimated window: not within 3 years on current trajectory.
• Brier forecast (overlay rule — binary, not EPS): "OpenBCI raises a priced equity round (Series A+) led by a growth- or crossover-stage fund by 2027-12-31" — p ≈ 0.20. (Per --watchlist rules, forecast.ts create is skipped in the loop — logged here in-dossier for a future human-gated pass.)
• private-watch.json back-fill (overlay write-back action): OpenBCI is absent from the watch list. Proposed entry for a future conversational privates.ts update — { beat: "bci", stage: "early-revenue", ipo_readiness: 1, lead_investors: "BITKRAFT, NaHCO3, re.Mind, Inertia", catalyst: "open-source EEG install base (40k+ units); Galea XR biosensing headset pre-orders; acquisition far likelier than IPO", dossier: "../menfem-research/companies/openbci/deep-dive-2026-06-30.md" }. (Not written here — wave boundary forbids editing research JSON; flagged for the human pass.)

Lens 12 · Bull vs Bear

Bull case. OpenBCI is the open-source standard of an industry that is about to matter. It owns the education-and-prototyping layer of BCI — 40,000+ units, 100+ countries, a deep GitHub community, the most channel-flexible research rig in its price class. The BCI market is forecast to compound at ~16–18% to $11–16B+ by 2034. If non-invasive consumer/XR neurotech inflects, OpenBCI is the brand every developer already knows, and Galea is a credible first-mover in multimodal-biosensing-meets-XR — a category Apple/Meta/Valve will eventually want. On ~$2–4M ever raised, the downside is capped and the optionality is real: a strategic acquirer could pay a large multiple of invested capital simply for the brand, community, and Galea IP. Capital-efficiency this extreme is itself a moat against a cash-bleed death.

Bear case (2–3 permanent-impairment risks). (1) It is a lifestyle hardware business mislabelled as a platform bet — open-source margins on $99–$999 boards do not fund the "neuro-personal-computer," and without venture-scale capital it cannot win the consumer future it describes; the gap between narrative and balance sheet never closes. (2) Galea depends on partners it doesn't control and has already pivoted twice (Valve→Varjo, Tobii→Pupil Labs) — if XR adoption stays niche (as it has for a decade) the one growth engine stalls, and a $25k headset has a tiny addressable buyer set. (3) The open-source ethos caps value capture — anyone can fork the designs; the brand is defensible but pricing power and recurring revenue are not, so even success looks like a modest-margin instruments business, not a venture return.

Pre-mortem (18 months out, thesis broke): It's end-2027. Galea sold a few dozen pilot units and never reached repeatable enterprise volume; XR stayed enthusiast-niche; OpenBCI couldn't clear a priced Series A and survives on hardware margin + small bridges; the neural-data state-law patchwork added compliance cost to a tiny revenue base. The company is fine — and exactly the same size, which for an investor is the failure mode: dead money, not a blow-up.

Are multiples too high? n/a — no priced valuation exists. The risk isn't an over-priced mark; it's that no priced mark exists because no growth investor will set one.

Contrarian view — what the market refuses to see: consensus lumps OpenBCI into "the BCI boom" alongside Neuralink. The contrarian truth is that OpenBCI is the anti-Neuralink — open not proprietary, non-invasive not surgical, customer-funded not billion-dollar-VC — and that identity, which makes it culturally important and capital-efficient, is precisely what disqualifies it as a venture-scale equity. It's the Wikipedia of neurotech: indispensable, beloved, and not a stock.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the money-making: it makes money selling commodity-silicon boards at hobbyist prices — a model with no recurring revenue, no pricing power, and an open licence that invites cloning. The "platform/data" upside that justifies any premium does not exist in the financials and has been "coming" since 2020.
• Revenue concentration / shift: revenue is concentrated in the mature research-board line; the growth is concentrated in one product (Galea) riding one rotating XR partner. If a cheaper integrated rig appears (or Muse/Neurosity push up-market, or a free academic clone proliferates), the defensible middle erodes from both sides.
• Why the moat is weaker than bulls think: the moat is mindshare, which does not convert to dollars in an open-source model. Emotiv has more research citations and is still capital-stranded after 23 years — citation leadership is not a path to a return.
• Most dangerous competitor bulls underestimate: not Neuralink — it's "good enough and cheaper": Muse/NeuroSky/Neurosity below, and the free, forkable open-source ecosystem OpenBCI itself created (its own designs can be undercut by a contract manufacturer).
• Worst capital-allocation / incentive issue: none unethical — but the founder-mission incentive is structurally misaligned with equity holders: a CEO optimising for "tools for everyone" will rationally not run the value-extracting playbook a financial investor needs.
• Assumptions that must hold for today's "price": there is no public price; the implicit bet — XR-biosensing becomes a real market this decade AND OpenBCI captures it without venture-scale capital — requires two low-probability things to both be true.
• If growth disappoints 20–30%: on a ~$4M base it's the difference between break-even and a small loss — survivable, but it pushes the priced round and any exit further out, deepening the dead-money risk.
• Single scenario that permanently impairs: XR adoption stalls for another decade (the base-rate outcome) → Galea never scales, no Series A clears, and OpenBCI is permanently a small, admirable instruments company. Plausibility: moderate-to-high — that is the last ten years of XR.

Lens 14 · Management Questions (ordered by information value)

1. Of your ~$4M (est.) revenue, what share is Galea vs. the legacy boards, and is Galea revenue repeatable enterprise volume or one-off pilots? (The entire thesis turns on this single split.)
2. You haven't priced an equity round since the 2021 seed — is that by choice (you're at/near break-even) or because you couldn't clear a step-up you'd accept? What is current cash runway?
3. What is the realistic exit you're building toward — a priced Series A, a strategic acquisition, or staying a profitable independent? Be specific about which.
4. Galea's anchor partners have changed twice (Valve→Varjo, Tobii→Pupil Labs). How do you de-risk a product whose viability depends on a third party's XR roadmap?
5. How many Galea units have actually shipped to paying enterprise customers, and who are the repeat buyers?
6. Your open-source licence means your designs can be cloned by any contract manufacturer. What concretely stops a low-cost fork from taking the research-board base?
7. The neural-data state laws (CO/CA/MT/CT) and the Senate→FTC referral are tightening. What compliance burden does that put on a company your size, and does it change your data posture?
8. What is gross margin on a Cyton/Ganglion today, and why did Ganglion go from $99 to $499 — what does that say about your unit economics at volume?
9. Is Galea a separate legal/financing entity (galea.co) or an OpenBCI product line? Would you raise Galea capital separately?
10. What is the single milestone that would let you raise a venture-scale round, and how far are you from it?
11. How do you convert 40,000+ shipped units and a huge GitHub community into recurring revenue without betraying the open-source ethos?
12. Who do you regard as your most dangerous competitor — the cheap consumer wearables below you, the clinical rigs above, or your own open ecosystem?
13. What is Joel Murphy's current role and ownership, and how is the founding team's equity/incentive structured?
14. If XR consumer adoption stays niche for another five years, what is OpenBCI's plan B for growth?
15. What would you have to believe to say OpenBCI is venture-scale rather than an excellent profitable small business — and do you believe it?

---